Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Share Capital (Details Textual)

Note 11 - Share Capital (Details Textual) - USD ($)					3 Months Ended		12 Months Ended	16 Months Ended
Note 11 - Share Capital (Details Textual) - USD ($)	Apr. 01, 2024	Jan. 31, 2024	Sep. 06, 2023	May 25, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Mar. 31, 2024	Feb. 29, 2024	Aug. 10, 2023	Dec. 09, 2022	Nov. 04, 2021
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs		$ 1,400,000
Common Stock, Shares Outstanding					15,717,701		7,942,363	15,717,701
Cash proceeds from issuing shares					$ 23,000
Common Shares [Member]
Cash proceeds from issuing shares					$ 23,000
Warrant [Member] \| Common Shares [Member]
Common warrants offering price		$ 1.71
Hanmi Pharmaceuticals Co Ltd [Member]
Proceeds from Issuance of Common Stock			$ 3,000,000
Underwriting costs (as percent)		7.00%
Professional fees		$ 400,000
Warrants to purchase common shares, exchange price		$ 1.71
Number of common shares held												215,703
Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Number of shares sold			668,449
Maximum [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Investment for ownership interest										$ 7,000,000
Percentage of investment										19.99%
Minimum [Member]
Private placement issuance percentage									20.00%
2023 Committed Equity Facility [Member]
Stock issuance program authorized shares				25,156
Common shares issued (in shares)							720,494
Proceeds from Issuance of Common Stock							$ 2,100,000
Stock Issuance Program, Authorized Amount				$ 25,000,000
Percentage of common shares outstanding.	19.99%			19.99%
Shares Issued, Price Per Share (in dollars per share)							$ 2.91
2023 Committed Equity Facility [Member] \| Initial Commitment Shares [Member]
Common shares issued (in shares)				7,547
Stock Issuance, Percent of Cash Commission to Broker				30.00%
2023 Committed Equity Facility [Member] \| First Back-End Commitment Shares [Member]
Common shares issued (in shares)				7,547
Stock Issuance, Percent of Cash Commission to Broker				30.00%
2023 Committed Equity Facility [Member] \| Commitment Shares [Member]
Common shares issued (in shares)					10,062		15,094
The 2022 ATM Offering [Member]
Common shares issued (in shares)						3,095
Proceeds from Issuance of Common Stock					$ 0	$ 34,000		$ 1,900,000
Stock Issuance Program, Authorized Amount											$ 50,000,000
Shares Issued, Price Per Share (in dollars per share)						$ 11.32
Proceeds from Issuance of Common Stock, Gross						$ 35,000		$ 1,900,000
Stock Issuance, Percent of Cash Commission to Broker					3.00%			3.00%
Cash proceeds from issuing shares						$ 34,000
The 2022 ATM Offering [Member] \| Common Shares [Member]
Common shares issued (in shares)						3,000
Cash proceeds from issuing shares						$ 34,000
The 2022 ATM Offering [Member] \| Subsequent Event [Member]
Common shares issued (in shares)	81,591
Proceeds from Issuance of Common Stock	$ 97,000
Shares Issued, Price Per Share (in dollars per share)	$ 1.22
Proceeds from Issuance of Common Stock, Gross	$ 100,000
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Common shares issued (in shares)		2,105,263
Proceeds from Issuance of Common Stock		$ 4,000,000
Shares Issued, Price Per Share (in dollars per share)		$ 1.9
Public Offering [Member]
Common shares issued (in shares)		5,649,122
Public Offering [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Proceeds from Issuance of Common Stock		$ 9,700,000
Premium Share Price Percent		11.00%
Over-Allotment Option [Member]
Common shares issued upon exercise of stock options		$ 736,842